RNA obtained by electrophoretic separation was transferred to a PVDF membrane and incubated with an antibody specific for the m5C methylation modification, followed by a chemiluminescent reaction to show the location of the bands to assess if the m5C methylation modification is present (33).

The second generation sequencing, a transcriptomic detection method, has been the preferred approach for RNA detection due to its low error and high accuracy. The examination of m6A and m5C alterations commonly uses nanopore technology, an amplification-free sequencing technique. Structural changes that occur as RNA or DNA passes through the nanopore result in differences in current blocking, which is translated into base sequences by a recurrent neural network (RNN) as a way of analyzing molecular signatures and locating regions of RNA methylation (34, 35).

In order to determine the degree of methylation in the test samples, the signal intensities of the sample RNAs are compared to standard curves obtained from known methylated and non-methylated control RNAs (34). Commercially available kits are sufficient for the assay.

RNA is broken down into nucleosides by enzymatic digestion, and these are then purified. Mass spectrometry is then used to separate the ribonucleosides and identify the methylated modified nucleosides. Individual molecules are identified and measured according to their mass-to-charge ratio (36). The method takes advantage of the fact that the modified nucleotide differs from its unmodified counterpart in terms of net charge, hydrophobicity, and polarity (34). The classical methods for the analysis of RNA methylation modification are one-dimensional (1D) or two-dimensional (2 D) thin-layer chromatography (TLC) and liquid chromatography-tandem mass spectrometry (LC-MS/MS) (36).

Spot hybridization, also known as slit hybridization, is a relatively simple method for the detection of methylation patterns in diverse RNA types. The membranes with RNA are incubated with specific antibodies or probes to determine the existence and level of methylation by the depth of the developed spots (37). This experiment should only be used to verify the presence of methylation and to compare the change in the overall abundance of methylation between different samples. However, it is equally significant to be careful to avoid contamination of the DNA, as this may affect the results.

ALYREF, also designated THOC4, is a heat-stable nuclear protein that has the unusual ability to recognize m5C sequences and act as a molecular chaperone. ALYREF is known to facilitate the dimerization of unfolded leucine zips by recognizing them, to activate transcription. It can also bind to specific molecules in the translational region of mRNAs, thereby regulating gene expression, mRNA egress from the nucleus and genome stability (38–42). In most tumors, ALYREF has a high expression level and is closely associated with tumor heterogeneity, immune infiltration, and a high mutation rate of TP53, which enhances the proliferation, migration, and invasive properties of tumor cells, as well as drug resistance, tumor progression and adverse prognosis (43–45). The activity of ALYREF is regulated by AKT-mediated phosphorylation, with reduced ALYREF phosphorylation observed to suppress cell proliferation and mRNA export (46).

YBX1 is a gene with a wide range of nucleic acid binding properties encoding a highly conserved cold-excited structural domain protein that plays a pivotal role in many basic biological functions, such as transcription, translation, DNA repair, and splicing of precursor mRNAs (47–49). YBX1 displaces translation initiation factors from messenger ribonucleic acid bodies and redistributes them to improve translation efficiency (50). However, the regulation of translation by YBX1 is not always positive. Studies have demonstrated a bell-curve relationship between the relative amount of YBX1 and the level of translation, with YBX1 acting as an inhibitor of translation when the relative amount of YBX1 is high (51–53). As a splicing regulator of messenger RNAs (mRNAs), YBX1 indirectly affects mRNA splicing and shear factors behavior by identifying particular sequences in precursor mRNAs (54). YBX1 can directly bind to m5C-methylated mRNAs and act to stabilize them (19, 20). In addition, YBX1 is essential for maintaining cardiomyocyte function. mTOR activation of YBX1 can transmit pathological signals and regulate protein synthesis in cardiomyocytes, which significantly contributes to the development of cardiac hypertrophy (55). YBX1, a known oncoprotein, shows high expression in a variety of tumors, and YBX1 can regulate tumor angiogenesis by releasing angiogenic factors into the extracellular microenvironment, playing a role as an oncogenic enhancer (56, 57).

YBX2 is a member of the Y-box protein family, and similar to YBX1, YBX2 also has an alanine/proline (A/P)-rich N-terminal domain, a variable C-terminal domain (CTD), and a highly conserved cold shock domain (CSD) (58). YBX2 is a major component of mRNP and regulates mRNA stability and translation (29, 59, 60). Because MAPK phosphorylates YBX2, ubiquitination-mediated degradation is suppressed. The accumulated YBX2 then activates brown adipose tissue, thereby promoting glucose utilization and lactic acid production in glycolysis (61). In addition, methylated YBX 2 can be recognized by ALYREF, promoting YBX 2 nucleation and increasing YBX 2 protein expression, which is an important way to regulate lipolysis (62). Moreover, YBX2 is essential for maintaining the normal function of germ cells (63). m5C methylation regulates the activity of YBX2, a novel m5C binding protein, and that can undergo liquid-liquid phase separation in vitro and in vivo (21). Pan-cancer analysis showed that YBX family genes are associated with most tumor progression and can predict tumor prognosis to a certain extent (64).

RAD52 is a multimeric cyclic DNA repair protein consisting of 418 amino acids. The human Rad52 protein, which is composed of a heptameric ring, resembles a windmill (65).In ROS-induced DNA double-strand break damage, RAD52 can preferentially bind to DNA: RNA hybrids containing m5C methylation-modified RNAs with the help of the m5C methyltransferase TRDMT1 to promote homologous recombination (23). This observation suggests that RAD52 may serve as a reader of m5C RNA in DNA: RNA hybrid at the DNA damage site and that m5C methylation modification of RNA is crucial for gene repair and maintaining genomic stability (66). Additionally, the activity, stability, and function of RAD52 are also affected by post-translational modifications such as phosphorylation and ubiquitination (67, 68). In tumors, RAD52 interacts with RNA polymerase-associated factor 1 (PAF1) to inhibit cisplatin and gemcitabine resistance (69).

Based on structural and functional studies of YTHDF2, it was found to be a versatile reader that recognizes M6A, M1A and M5C (70, 71). Dai et al. demonstrated that three aromatic amino acid residues in the hydrophobic pocket of YTHDF2 that bind m6A can bind directly to m5C-methylated RNA. Considering that YTHDF2 recognizes multiple methylated forms, whether YTHDF2 acts on the m5C site can be verified by immunoprecipitation in vitro pull-down assays and LC-MS/MS, and can also be distinguished by the difference in YTHDF2 binding to the m5C and m6A docking structural domains (22). Functionally, YTHDF2 participates in the processing of precursor ribosomal RNAs (pre-rRNAs) in an m5C-dependent manner and regulates translation (22, 72). Histone lactation controls YTHDF2 expression, and tumors with high levels of YTHDF2 are associated with a poor prognosis. Additionally, YTHDF2 regulates immune processes by affecting immune cell infiltration in the tumor microenvironment (73, 74). The deletion of YTHDF2 in the tumor microenvironment has been observed to result in increased apoptosis and impaired suppression of Treg cells (75). Additionally, it has been shown to promote reprogramming of tumor-associated macrophages, enhance antigen cross-presentation, inhibit tumor growth, and enhance the efficacy of PDL-1 antibodies (76, 77). As YTHDF2 interacts with more than one type of methylation modification, the mechanism by which it acts needs to be further explored and differentiated. However, the role of YTHDF2 in tumor is still controversial, showing very different effects in different cancer types. For example, it plays a dual role in gastric cancer (78, 79). A comprehensive and detailed examination is necessary to clarify its precise mechanism of action.

FMRP is an RNA-binding protein with three structural domains: the N-terminus, the central structure, and the C-terminus, which is associated with the structure and function of synapses, is involved in the exit of mRNA from the nucleus, and also has a wide range of regulation of gene expression (80, 81). Early nervous system development requires FMRP to identify and bind mRNAs in the hippocampus and cerebral cortex, which are critical for memory and learning (82). Furthermore, FMRP plays a role in RNA methylation modification as an m5C reader, facilitates the interaction between the methyltransferase TRDMT1 and the demethylase TET1, influences transcription and translation, and contributes to DNA damage repair and cell survival (24, 83). Beyond its role in gene regulation, FMRP is also important in metabolic processes. It has been demonstrated that FMRP deficiency increases hepatic protein synthesis and affects lipid metabolism, indicating that FMRP is involved in the regulation of systemic metabolic homeostasis (84). In solid tumors, FMRP up-regulation contributes to poor prognosis, inhibits immune attack, promotes tumor growth, immune escape and epithelial-mesenchymal transition (EMT) conversion (85, 86).

SRSF2 belongs to the family of RNA-binding proteins known as serine/arginine-rich (SR) proteins, which are involved in constitutive and selective splicing of RNAs and suppress intron splicing (87–89). SRSF2 contains an RNA recognition motif (RRM) and an RS domain, the former for binding to RNA and the latter for binding to other proteins. Additionally, the interactions between different SR splicing factors are realized in the RS domain (90). It has been reported that SR proteins play a role in the process of mRNA egress and translation, in addition to RNA splicing (91). Aberrant expression of SRSF2 is closely associated with tumorigenesis (92). Recent studies find that knockdown of NSUN2 decreases RNA methylation levels, reduces SRSF2 binding, and alters RNA splicing, which evidences SRSF2 can act as an m5C reader and may be associated with the development of malignancy (25, 93). Besides, SRSF2 has been linked to immune system depletion in the tumor microenvironment. It is a potential therapeutic target for reversing immune depletion because it regulates the transcription of immune checkpoint genes by influencing signal transduction and promoter recruitment (94). SRSF2 is a key molecule for cell survival and not only has a role in tumors but also regulates myocyte proliferation and myogenesis by preventing premature aging, differentiation, and apoptosis of myocytes (95). Moreover, SRSF2 acts as a strong transcriptional activator that promotes hepatic energy homeostasis and bile acid metabolism. Mutation or deletion in the expression of SRSF2 can lead to aberrant hepatic splicing, metabolic dysfunction, bile acid accumulation, and the subsequent induction of endoplasmic reticulum stress and oxidative stress, ultimately leading to liver failure (96).

Hepatocellular carcinoma (HCC) is the material cause of morbidity and mortality among all cancers, and is a major threat to global health (97). The majority of liver cancer patients are concentrated in Asia, with China having the most liver cancer cases (98, 99). The low survival rates of liver cancer creates a significant challenge for treating this disease (100, 101). As a binding protein for m5C methylation, ALYREF can stabilize RNA and activate subsequent signaling pathways to exert a tumorigenic effect (102). Xue et al. found that ALYREF deficiency can inhibit hepatocellular carcinoma cells proliferation and tumor growth, increase the rate of apoptosis, and is associated with tumor immune infiltration (103, 104). In hepatocellular carcinoma, the overexpression of YBX1 remodels the tumor microenvironment, increasing the infiltration of immune cells and the transcription of PD-L1 (105, 106). YBX1 interacts with circular RNA to promote metastasis and drug resistance of liver cancer: circASH2 influences the liquid-liquid phase separation and cytoskeletal remodeling of YBX1, thereby promoting the metastasis of hepatocellular carcinoma (107, 108); cFAM210A binds to YBX1, which reduces YBX1 phosphorylation and inhibits the trans-activating effect on EMT. At the same time, cFAM210A is regulated by YTHDF2, which induces cFAM210A degradation and promotes hepatocellular carcinoma progression (109). The elevated expression of RAD52 in hepatocellular carcinoma is linked to age and gender, and it is associated with promoting proliferation and migration of hepatocellular carcinoma cells (110). YTHDF2 is associated with stemness and drug resistance in hepatocellular carcinoma cells, improving genomic stability and promoting immune escape and angiogenesis, while also facilitating hepatocellular carcinoma metastasis in vivo (111–114). SRSF2 is frequently mutated or overexpressed in cancerous cells, and SRSF2 deletion can stimulate the regeneration of hepatic progenitor cells and the activation of oncogenes in hepatocellular carcinoma, which increases the proliferative and tumorigenic potential of hepatocellular carcinoma cells, mediates drug resistance, and promotes the progression of hepatocellular carcinoma (115, 116). FMRP is overexpressed in hepatocellular carcinoma, promotes the translation of STAT3, and can bind to STAT3 mRNA, thereby facilitating its localization to cellular protrusions and the promotion of hepatocellular carcinoma metastasis (117).

Pancreatic cancer is globally recognized as one of the deadliest malignant tumors, and clinical treatment is facing great challenges. There is an urgent demand to explore its pathogenesis, discover therapeutic targets, and prevent its progression more effectively (118). ALYREF can affect amino acid metabolism in pancreatic cancer cells, promote immune escape, and is associated with poor prognosis (119). YBX1 directly promotes mucin expression and establishes a barrier to prevent chymotrypsin from digesting pancreatic cancer cells, a mechanism that ensures the survival of pancreatic cancer cells in the pancreatic microenvironment (120). Overexpression of YBX1 in pancreatic cancer binds to the promoter of GSK3β, resulting in upregulation of CBX3, which activates TGF-β signaling to regulate the cell cycle and promotes the growth and proliferation of pancreatic cancer cells (121, 122). YBX1 also promotes IL-18 transcription, increases immune cell infiltration, and regulates the immune microenvironment in pancreatic cancer (123). YTHDF2 regulates EMT via YAP, which in turn hinders the migration and invasion of pancreatic cancer cells (124).

Esophageal cancer belongs to malignant tumors of the digestive system and progresses rapidly in the later stages. As the tumor grows in size, it can nearly completely obstruct the esophagus, which greatly reduces patients’ quality of life. Research shows that esophageal cancer occurs more frequently in men, with higher morbidity and mortality rates compared to women (125). m5C, one of the most common RNA modifications, plays an important role in esophageal cancer progression. YBX1 is upregulated in most cancers and esophageal cancer is no exception. Both in vivo and in vitro, YBX1 promotes the proliferation, migration, and invasion of esophageal cancer cells (5). In esophageal carcinogenesis, long non-coding RNAs are significant (126). LINC00941 can interact with YBX1, bind to the promoter region of SOX2, upregulate SOX2 transcription, increase RNA stability, and promote the malignant phenotype of esophageal cancer (127). MiR-323a-3p inhibits the proliferation, migration, and invasion of esophageal cancer cells by regulating FMR1 (128).

Breast cancer is the most prevalent malignant tumor and the second principal cause of cancer deaths in women (129, 130). ALYREF has been demonstrated to promote the development of breast cancer by affecting transcriptional regulation and mitochondrial energy metabolism, and regulate the growth, apoptosis, and migration of breast cancer cells (6). Jin et al. found that ALYREF, in addition to regulating the nuclear export of mRNA, also affects the stemness of breast cancer cells and is associated with adriamycin resistance (131). In breast cancer, YBX1 is linked to genetic stability; it can interact with m5C methyltransferase NSUN2 to influence mRNA stability, protein synthesis, and promote tumor progression (132–134). YBX1 regulates the invasion and migration of breast cancer cells by down-regulating the levels of the protein coronin-1C (135). The YBX1 protein has been demonstrated to regulate the proliferation of breast cancer cells through the PI3K/AKT/mTOR signaling pathway. Furthermore, there is evidence that YBX1 is connected to the development of tamoxifen resistance (136). The interaction between DSCAM-AS1 and YBX1 in positive feedback regulates the expression of ERα and promotes the progression of breast cancer (137). Wu et al. identified a new piRNA, named piR-YBX1. This piRNA can bind directly to YBX1, resulting in a reduction in the levels of both mRNA and protein. Additionally, YBX1 has been observed to bind to RAF1, an important role in the MAPK signaling pathway, which plays a crucial role in the development and progression of triple-negative breast cancer (138). RAD52 is connected to the breast cancer susceptibility genes BRCA1 and BRCA2. Research has shown that mutations in RAD52 can suppress certain BRCA2-related phenotypes in breast cancer (139, 140). In cells lacking BRCA2, overexpression of RAD52 can compensate for the loss of BRCA2-associated function. However, simultaneous deficiencies of both RAD52 and BRCA2 have been shown to be lethal to cells (141). YTHDF2 reverses RNA demethylase-induced alterations in cellular phenotype by increasing mRNA stability (72). Furthermore, it has been found to promote cell proliferation, invasion, and tumorigenic properties in vitro, as well as promoting osteolytic metastasis of breast cancer in vivo (142, 143). Triple-negative breast cancer is characterized by the absence of specific markers and therapeutic targets, which contributes to worse outcome and high recurrence and metastasis rates. The main treatment modalities for triple-negative breast cancer are chemotherapy and immunotherapy. YTHDF2 has been reported to affect the pre-tumor phenotypic polarization of macrophages and antigen-presenting signals between immune cells in triple-negative breast cancer. Furthermore, it also inhibits immune activity and associates with drug resistance (144). SRSF2, another m5C methylation binding protein, promotes angiogenesis under hypoxic conditions by selectively splicing vascular endothelial growth factor A (VEGFA) and is associated with poor prognosis in breast cancer (145). Similar to other tumors, FMRP expression is elevated in breast cancer. Furthermore, there are considerable variations in FMRP expression among metastatic breast cancer lesions, with low expression in the brain and bones and high expression in the liver and lungs. Consequently, FMRP is regarded as a prognostic factor for site-specific metastasis (146).

Lung cancer has a high incidence rate in both men and women, and common types include lung adenocarcinoma, squamous cell carcinoma, and small cell lung cancer, of which adenocarcinoma and squamous cell carcinoma are collectively known as non-small cell lung cancer (NSCLC) (97, 147). A recent study has indicated that ALYREF and YTHDF2 are correlated with mRNA stability in lung adenocarcinoma and act on the YAP signaling pathway to alter immune cell infiltration in the tumor microenvironment (148, 149). Furthermore, they have been shown to enhance the secretion of exosomes and activate the downstream pathway in lung adenocarcinoma by regulating YAP transcription, which promotes drug resistance, tumor progression, and metastasis (150, 151). In lung adenocarcinoma, YBX1 is highly expressed and binds to the promoter region of CDC25a and HOXC8, thereby regulating cell cycle progression, cell proliferation, and apoptosis (152, 153). The Runx3-miR-148a-3p axis targets and regulates YBX1, adjusting the levels of multiple genes like Cyclin D1 and MMP2. This affects the proliferation, migration, and invasion of non-small cell lung cancer, and promotes NSCLC progression (154). `The regulation of YBX1 on the stemness of NSCLC is complex: on the one hand, it can inhibit the expression of MUC5AC and the integrin β4/pSrc/p53 signaling pathway, reducing lung cancer cell stemness and increasing the therapeutic sensitivity of erlotinib (155). On the other hand, YBX1 can promote the activation of NANOG to enhance the stemness and spheroidal ability of non-small cell lung cancer and regulates MUC1 transcription to promote cancer metastasis and stem cell properties (156, 157). The phase separation of YBX1 is identified as a key process in the development of non-small-cell lung cancer, affecting carcinogenesis and progression by regulating the biological behavior of cancer cells (158). RAD52 is expressed at high levels in non-small cell lung cancer, and regulates cell cycle and apoptosis and correlates with tumor size, degree of differentiation, lymphatic metastasis, and susceptibility (159, 160). SRSF2 is overexpressed in non-small cell lung cancer and interacts with long non-coding RNAs to up-regulate the expression of VEGFR1-i13, affecting the proliferation and invasion of lung cancer cells (161–163). In neuroendocrine lung tumors, SRSF2 also makes a difference. Highly expressed SRSF2 acts as a cell cycle regulatory protein that regulates the proliferation of lung cancer cells and promotes cancer progression (164).

Prostate cancer is a common malignant tumor in males, representing a substantial risk to the quality and longevity of life (165). Methylation modification of RNA has a visible impact on prostate cancer. The m5C-binding protein YBX1 inhibits ubiquitination of the androgen receptor, increasing intracellular androgen levels and stability. While AURKA phosphorylates residues of YBX1 and promotes its stabilization and nuclear translocation so that a positive feedback loop is formed and plays an important role in prostate cancer (166). YTHDF2 promotes mRNA stabilization and protein expression in androgen-negative prostate cancer, upregulates EMT-related factors, and activates the AKT pathway, which in turn promotes cell proliferation to promote metastasis (114, 167). Besides, A high level of SRSF2 expression is correlated with an adverse prognosis in prostate cancer (168).

Bladder cancer is a malignant cancers with a high recurrence and metastasis rates and has a poor prognosis (169, 170). Studies show that bladder cancer is strongly associated with genetic mutations and partly with epigenetic dysregulation (171, 172). In bladder cancer, ALYREF enhances the stability of mRNA encoding the glycolysis rate-limiting enzyme PKM2 in an m5C-dependent manner, upregulates PKM2 expression, and promotes the progression and deterioration of bladder cancer (173). ALYREF recognizes the NSUN2 locus on methylated mRNA and promotes mRNA stabilization to enhance the proliferation and invasion of bladder cancer cells in an m5C-dependent manner (28). The study revealed that YBX1 is crucial in bladder carcinogenesis and the tumorigenic effects of YBX1 were closely associated with glycolysis (19). Furthermore, the upregulation of glycolytic enzymes to facilitate glycolysis by regulating c-MYC and HIF1-α expression (56). SRSF2 interacts with miR-193a-3p, and compelling evidence suggests that this interaction is strongly associated with multidrug resistance in bladder cancer (174).

Due to the unique disease characteristics of colorectal cancer, symptoms usually appear at a late stage, resulting in most cases being diagnosed late and treatment being passive. Research find that the morbidity of colorectal cancer is generally on the rise (175). Therefore, clarifying the pathogenesis of colorectal cancer will provide more possibilities for treatment. In colorectal cancer, the function of YBX1 is regulated by non-coding RNAs, transcription factor NF-κb, etc, and is associated with the activation of various signaling pathways (176, 177). Lnc-SOX9-4 inhibits YBX1 degradation, stabilizes YBX1 protein levels, and accelerates the proliferation and metastasis of colorectal cancer cells (178). YBX1 is an m5C reader and can also be modified by methylation, and the modified YBX1 shows different effects in tumors: when methylated by PRMT5, YBX1 can inhibit the growth, migration, and invasion of colorectal cancer cells (176). Phosphorylated YBX1 activates the NF-κB signaling pathway and promotes colorectal cancer progression (179). The reprogramming of glucose metabolism by YBX1 and NSUN2 in an m5C-dependent manner promotes lactate production and accumulation. Furthermore, lactate accumulation positively feedback regulates the pro-cancer effects of NSUN2 by promoting NSUN2 transcription (32). YTHDF2 is widely involved in the pathogenesis of colorectal cancer, recognizing methylated XIST and mediating its degradation to inhibit colorectal cancer progression (180). YTHDF2 also plays a role in aerobic glycolysis in P53 wild-type colorectal cancer and suppresses the malignant phenotype of the tumor (181). In terms of treatment, YTHDF2 increases the sensitivity of post-surgical radiotherapy in colorectal cancer patients (182). The expression of SRSF2 in colorectal cancer is apparently higher than that in normal tissues. The high expression of SRSF2 acts as a cell cycle regulator, promoting the proliferation of colorectal cancer cells both in vivo and in vitro, and contributing to the progression of colorectal cancer (92). Overexpression of FMRP and RAD52 is associated with colorectal cancer progression. FMRP regulates necrotic activation of cancer cells by controlling the expression of RIPK1 and results in poorer prognosis (66, 183).

Gastric cancer is one of the most common malignancies, with high malignancy and lethality. It is prone to metastasis, recurrence, and drug resistance, and is the second most common cause of cancer death (184). The study indicated that ALYREF has an influence on accelerating cell proliferation and metastasis by regulating the cell cycle and preventing cell apoptosis (185). Long non-coding RNAs (lncRNAs) have been reported to play a multitude of roles in cancer. One example is the lncRNA PIN1P1, which has a high expression in gastric cancer and promotes cancer progression by interacting with the YBX1 (186). Under hypoxic conditions, HIF-1 mediates high expression of YTHDF2, which is correlated with unfavorable prognosis of gastric cancer and increases the expression and stability of CyclinD1, promoting the proliferation of gastric cancer cells, and being associated with chemotherapy resistance (78). In contrast, the study conducted by Shen et al. reveals that YTHDF2 has the potential to impede the proliferation of gastric cancer cells by negatively modulating the FOXC2 signaling pathway (79). It can be seen that YTHDF2 exercises multiple functions in gastric cancer, acting on different molecules or pathways and producing distinct regulatory effects on tumors. Acetylated SRSF2 promotes the methylation of precursor RNA in gastric cancer cells, stimulates cell proliferation and migration, and mediates the malignant phenotype of gastric cancer cells, which correlates with poor prognosis of gastric cancer (187).

YBX1 functions as a splicing factor, upregulating pro-carcinogenic VEGF165 to promote the proliferation, migration, and invasion of osteosarcoma cells and induce angiogenesis (188). YTHDF2 plays a role in osteosarcoma demethylation, inactivating the STAT3 pathway and inhibiting tumor cell proliferation, while simultaneously blocking the cell cycle and accelerating apoptosis (189). YBX1 is a key molecule in acute myeloid leukemia cell survival, regulating cell proliferation, apoptosis, cell cycle, and cell signal transduction (190). In ovarian cancer, high expression of YBX1 and YTHDF2 is relevant to poor prognosis, with YBX1 up-regulating the expression of E2F1 by a phase separation manner, leading to tumor progression (31, 191). In addition, YBX1 is closely related to drug resistance in ovarian cancer, improving the ability of cell gene damage repair by increasing the stability of mRNA, thereby enhancing the resistance of tumor cells to platinum-based chemotherapy drugs (192). YBX2 promotes the properties of endometrial cancer stem cells and enhances their pellet-forming ability and chemotherapy resistance (193). YBX1 inhibits apoptosis of renal clear cell carcinoma cells, promotes migration and invasion, and is a potential prognostic marker and therapeutic target for renal cell carcinoma (194). SRSF2 is not only involved in alternative splicing but also related to the expression of apoptotic genes. The expression of SRSF2 in renal clear cell carcinoma is lower, which inhibits the activity of caspase-9 and enhances the survival ability of renal cell carcinoma (195). m5C binding proteins YBX1, YBX2, and ALYREF are highly expressed in head and neck squamous cell carcinoma, accelerating cell proliferation and tumor metastasis, and are associated with poor prognosis (196–199).